The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Neoadjuvant Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Neoadjuvant Therapy


High impact information on Neoadjuvant Therapy


Chemical compound and disease context of Neoadjuvant Therapy


Biological context of Neoadjuvant Therapy


Anatomical context of Neoadjuvant Therapy


Associations of Neoadjuvant Therapy with chemical compounds


Gene context of Neoadjuvant Therapy

  • Expression of GST pi and TS was also significantly correlated with decreased OS after neoadjuvant treatment [23].
  • CONCLUSIONS: To the author's know the current study is the first to date to demonstrate that u-PA system expression may serve as a predictor of risk in intestinal metaplasias and preoperative biopsies, implicating consequences for neoadjuvant therapy [26].
  • Anastrozole, an orally active, nonsteroidal aromatase inhibitor, was evaluated in a randomized, double-blind, single-center study to determine its efficacy as neoadjuvant therapy in postmenopausal women with newly diagnosed, estrogen receptor-rich, locally advanced or large (>3 cm), operable breast cancers [11].
  • RNA was isolated from endoscopic biopsies (paired tumor and normal tissue) before neoadjuvant treatment and quantitative real-time reverse transcriptase-PCR (Taqman) assays were done to determine COX-2 mRNA expression levels standardized for beta-actin [27].
  • VEGF levels were unaffected by neoadjuvant treatment but fell significantly on the first day after operation (652 versus 1057 pg/ml before operation; P < 0.05) [28].

Analytical, diagnostic and therapeutic context of Neoadjuvant Therapy


  1. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Buzdar, A.U., Ibrahim, N.K., Francis, D., Booser, D.J., Thomas, E.S., Theriault, R.L., Pusztai, L., Green, M.C., Arun, B.K., Giordano, S.H., Cristofanilli, M., Frye, D.K., Smith, T.L., Hunt, K.K., Singletary, S.E., Sahin, A.A., Ewer, M.S., Buchholz, T.A., Berry, D., Hortobagyi, G.N. J. Clin. Oncol. (2005) [Pubmed]
  2. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. De Andrés, L., Brunet, J., López-Pousa, A., Burgués, J., Vega, M., Tabernero, J.M., Mesía, R., López, J.J. J. Clin. Oncol. (1995) [Pubmed]
  3. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Brücher, B.L., Weber, W., Bauer, M., Fink, U., Avril, N., Stein, H.J., Werner, M., Zimmerman, F., Siewert, J.R., Schwaiger, M. Ann. Surg. (2001) [Pubmed]
  4. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Febbo, P.G., Thorner, A., Rubin, M.A., Loda, M., Kantoff, P.W., Oh, W.K., Golub, T., George, D. Clin. Cancer Res. (2006) [Pubmed]
  5. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Pozzo, C., Basso, M., Cassano, A., Quirino, M., Schinzari, G., Trigila, N., Vellone, M., Giuliante, F., Nuzzo, G., Barone, C. Ann. Oncol. (2004) [Pubmed]
  6. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Ayers, M., Symmans, W.F., Stec, J., Damokosh, A.I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., Valero, V., Royce, M., Arun, B., Whitman, G., Ross, J., Sneige, N., Hortobagyi, G.N., Pusztai, L. J. Clin. Oncol. (2004) [Pubmed]
  7. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. Therasse, P., Mauriac, L., Welnicka-Jaskiewicz, M., Bruning, P., Cufer, T., Bonnefoi, H., Tomiak, E., Pritchard, K.I., Hamilton, A., Piccart, M.J. J. Clin. Oncol. (2003) [Pubmed]
  8. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. Ferrandina, G., Lauriola, L., Distefano, M.G., Zannoni, G.F., Gessi, M., Legge, F., Maggiano, N., Mancuso, S., Capelli, A., Scambia, G., Ranelletti, F.O. J. Clin. Oncol. (2002) [Pubmed]
  9. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Salazar, M., Barata, A., André, S., Venâncio, J., Francisco, I., Cravo, M., Nobre-Leitão, C. Gut (2006) [Pubmed]
  10. Effect of glutamine on methotrexate efficacy and toxicity. Rubio, I.T., Cao, Y., Hutchins, L.F., Westbrook, K.C., Klimberg, V.S. Ann. Surg. (1998) [Pubmed]
  11. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Dixon, J.M., Renshaw, L., Bellamy, C., Stuart, M., Hoctin-Boes, G., Miller, W.R. Clin. Cancer Res. (2000) [Pubmed]
  12. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Raoul, J.L., Le Prisé, E., Meunier, B., Heresbach, D., Campion, J.P., Launois, B. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  13. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Miller, W.R., Dixon, J.M., Macfarlane, L., Cameron, D., Anderson, T.J. Eur. J. Cancer (2003) [Pubmed]
  14. Combined cis-platinum plus radiation antitumor activity in locoregionally advanced squamous cell esophageal cancer. Kolarić, K., Nagy, B., Roth, A., Zupanc, D., Luetić, J., Tometić, Z. Oncology (1988) [Pubmed]
  15. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study. Estévez, L.G., Sánchez-Rovira, P., Dómine, M., León, A., Calvo, I., Jaén, A., Casado, V., Rubio, G., Daz, M., Miró, C., Lobo, F. Semin. Oncol. (2004) [Pubmed]
  16. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Davis, D.W., Buchholz, T.A., Hess, K.R., Sahin, A.A., Valero, V., McConkey, D.J. Clin. Cancer Res. (2003) [Pubmed]
  17. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Anderson, T.J., Dixon, J.M., Stuart, M., Sahmoud, T., Miller, W.R. Br. J. Cancer (2002) [Pubmed]
  18. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. Miller, W.R., Anderson, T.J., White, S., Evans, D., Krause, A., Dixon, J.M. Endocr. Relat. Cancer (2005) [Pubmed]
  19. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Su, S.L., Heston, W.D., Perrotti, M., Cookson, M.S., Stroumbakis, N., Huyrk, R., Edwards, E., Brander, B., Coke, J., Soloway, S., Lewis, A., Fair, W.R., Perroti, M. Urology (1997) [Pubmed]
  20. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin. D'Agostino, G., Distefano, M., Greggi, S., Salerno, M., Ferrandina, G., Poerio, A., Mancuso, S., Scambia, G. Cancer Chemother. Pharmacol. (2002) [Pubmed]
  21. Stage I endometrial carcinoma: the role of neoadjuvant progesterone therapy. Haylock, B.J., Murrell, D.S., Bourne, H., Acworth, P. Clinical oncology (Royal College of Radiologists (Great Britain)) (1993) [Pubmed]
  22. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Tuynman, J.B., Buskens, C.J., Kemper, K., ten Kate, F.J., Offerhaus, G.J., Richel, D.J., van Lanschot, J.J. Ann. Surg. (2005) [Pubmed]
  23. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Shiga, H., Heath, E.I., Rasmussen, A.A., Trock, B., Johnston, P.G., Forastiere, A.A., Langmacher, M., Baylor, A., Lee, M., Cullen, K.J. Clin. Cancer Res. (1999) [Pubmed]
  24. Antimetastatic intraoperative chemotherapy of human colon tumors in the livers of nude mice. Rashidi, B., An, Z., Sun, F.X., Moossa, A.R., Hoffman, R.M. Clin. Cancer Res. (2000) [Pubmed]
  25. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Geisler, J., Detre, S., Berntsen, H., Ottestad, L., Lindtjørn, B., Dowsett, M., Einstein Lønning, P. Clin. Cancer Res. (2001) [Pubmed]
  26. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Beyer, B.C., Heiss, M.M., Simon, E.H., Gruetzner, K.U., Babic, R., Jauch, K.W., Schildberg, F.W., Allgayer, H. Cancer (2006) [Pubmed]
  27. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Xi, H., Baldus, S.E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R., Ling, F.C., Dienes, H.P., Bollschweiler, E., Moenig, S., Mueller, R.P., Hoelscher, A.H., Schneider, P.M. Clin. Cancer Res. (2005) [Pubmed]
  28. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. McDonnell, C.O., Harmey, J.H., Bouchier-Hayes, D.J., Walsh, T.N. The British journal of surgery. (2001) [Pubmed]
  29. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Konski, A., Hoffman, J., Sigurdson, E., Haluszka, O., Engstrom, P., Cheng, J.D., Cohen, S.J., Watson, J.C., Eisenberg, D., McGarrity, E., Freedman, G., Meropol, N.J. Semin. Oncol. (2005) [Pubmed]
  30. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Witjes, W.P., Schulman, C.C., Debruyne, F.M. Urology (1997) [Pubmed]
  31. mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Wang, C.S., LaRue, H., Fortin, A., Gariépy, G., Têtu, B. Breast Cancer Res. Treat. (1997) [Pubmed]
  32. Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue. Franke, U.F., Wittwer, T., Kaluza, M., Albert, M., Becker, V., Roskos, M., Lessel, M., Wahlers, T. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. (2004) [Pubmed]
  33. Aromatase inhibitors. Cunnick, G.H., Mokbel, K. Current medical research and opinion. (2001) [Pubmed]
WikiGenes - Universities